STAT June 17, 2024
Meghana Keshavan

Hello! Today, we talk about the uptick in physicians using ctDNA to determine if resected cancers are truly gone, we see the FDA offering new guidelines for Covid-19 vaccines, and more.

The need-to-know this morning

  • Takeda reported negative results from two Phase 3 studies investigating the use of an experimental drug called soticlestat for the treatment of Dravet syndrome and Lennox-Gastaut syndrome — rare forms of epilepsy. Shares of Ovid Therapeutics, which had licensed soticlestat to Takeda, fell sharply in early trading.

More physicians are using ctDNA tests

Clinicians are increasingly using blood tests that measure circulating tumor DNA, or ctDNA, to figure out whether any cancerous cells remain after a malignancy is removed. One of the most...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: FDA, Govt Agencies, Healthcare System, Patient / Consumer, Provider, Public Health / COVID
Related Articles:
FDA warns GLP-1 compounder over safety rules
GLP-1 drug approvals: A breakdown
Rethinking FDA’s Accelerated Approval Pathway: New Draft Guidances and Implications for Drug Companies
FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use
Certainty vs. speed: How do patients feel about the tradeoff for new cancer drugs?

Share This Article